Network meta-analysis reveals lebrikizumab matches dupilumab and outperforms tralokinumab in moderate-to-severe atopic dermatitis, indicating distinct efficacy tiers across systemic therapies.
Among biologics, lebrikizumab was comparable to dupilumab and superior to tralokinumab in improving response rates at week 16. Upadacitinib 30 mg was the only JAK inhibitor with superior response rates compared to lebrikizumab.
No takes yet. Share an insight, caveat, or question.
Silverberg et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: